Inclusion criteria:
Patients diagnosed with grade II to IV acute Graft versus host disease (GVHD)
whose response to treatment with corticosteroids equal to or more than 2 milligrams per kilogram is poor, and the disease symptoms progress in three days or have stable disease for five days
Patients over 18 years old
Patients of both sexes
Signed written informed consent
Exclusion criteria:
Patients who have recurrence of the main disease (cancer)
Patients who, in the differential diagnosis of clinical symptoms, have causes other than acute graft versus host disease (aGVHD) indicating the patient, such as patients with symptoms Sinusoidal Obstruction Syndrome (SOS), maculopapular skin rashes with drug or viral causes or Engraftment Syndrome, viral diarrheas, etc
Patients who have been prescribed Infliximab
The presence of an active uncontrolled infection, including a significant bacterial, fungal, viral or parasitic infection that requires treatment
Presence of recurrent primary malignancy, or those treated for recurrence after Hematopoietic Cell Transplantation (HCT), or those who may require rapid removal of immunosuppression as pre-emergency treatment of primary recurrence
Have unresolved venous occlusion disease
Patients who have any underlying or current medical or psychiatric problems that the researcher thinks may be a disorder (uncontrolled infection, cardiovascular failure, and pulmonary pressure)
Patients who have any allergy to blood products